<Suppliers Price>

Tildrakizumab

Names

[ CAS No. ]:
1326244-10-3

[ Name ]:
Tildrakizumab

Biological Activity

[Description]:

Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related
Research Areas >> Inflammation/Immunology

[Target]

IL-23[1]


[In Vitro]

Tildrakizumab 抑制表达人 IL-23Rα 和 IL-12Rβ1 受体的 HeLa 细胞中 IL-23 诱导的 STAT3 信号，IC50 为 23 pM[2]。 Tildrakizumab 通过负变构调节降低 IL-23 对 IL-23Rα 的亲和力[2]。

[In Vivo]

Tildrakizumab (100 mg/kg，皮下注射，每 2 周一次，最多 9 个月) 在食蟹猴中具有良好的耐受性 (毒性研究)[3]。

[References]

[1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.  

[2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.  

[3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.  

Chemical & Physical Properties

[ Molecular Weight ]:
144.4 (kDa)

Related Compounds